Physician profile
Jonathan L Sack
NPI 1194780726
$2,326.58
in general payments reported to CMS, 2019-2025
36 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $394 · 2021: $413 · 2022: $370 · 2023: $241 · 2024: $276 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $750.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $520.28 | 2019-2025 | Sublocade |
| Abbvie INC. | $514.98 | 2021-2025 | Vraylar |
| Pfizer INC. | $154.07 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $121.70 | 2020-2023 | Hetlioz |
| Kowa Pharmaceuticals America, INC. | $114.99 | 2019-2022 | |
| Allergan, INC. | $88.57 | 2019-2020 | |
| Astellas Pharma US INC | $60.88 | 2023-2025 | Veozah, Myrbetriq |
| Galderma Laboratories, L.P. | $50.54 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $49.46 | 2023-2024 | Rexulti |
| Novo Nordisk INC | $48.43 | 2019-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $48.08 | 2020-2021 | |
| Amgen INC. | $47.92 | 2022-2024 | Krystexxa |
| Braeburn INC. | $43.20 | 2023-2025 | Brixadi |
| Takeda Pharmaceuticals U.S.A., INC. | $37.31 | 2020-2021 | |
| Lilly USA, LLC | $34.40 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $33.53 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $30.79 | 2019 | |
| Titan Pharmaceuticals, INC. | $26.03 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.84 | 2020 | |
| Therapeuticsmd, INC. | $21.14 | 2019 | |
| Eisai INC. | $20.91 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.89 | 2022 | |
| Depuy Synthes Sales INC. | $19.13 | 2019 | |
| Bausch Health US, LLC | $17.45 | 2024 | Wellbutrin, Aplenzin |
| Shire North American Group INC | $17.31 | 2019 | |
| Idorsia Pharmaceuticals US INC | $17.00 | 2023 | Quviviq |
| Halozyme INC | $16.27 | 2023 | |
| Radius Health, INC. | $16.27 | 2019 | |
| Tolmar, INC. | $15.94 | 2023 | |
| Exact Sciences Corporation | $14.94 | 2024 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $14.38 | 2022 | |
| Merck Sharp & Dohme LLC | $14.09 | 2019 | |
| Acella Pharmaceuticals, LLC | $14.09 | 2024 | NP Thyroid 60 |
| Redhill Biopharma INC. | $13.89 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.08 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Sack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.